Biophytis participates in the 17th SCWD Congress and hosts an Obesity Investor Call

Communiqué de presse

Biophytis participates in the 17th SCWD Congress  and hosts an Obesity Investor Call

Paris, France and Cambridge (Massachusetts, USA), [December 2, 2024] – 7:00 AM – Biophytis SA (Euronext Growth Paris: ALBPS; Nasdaq CM: BPTS), a clinical-stage biotechnology company specializing in developing treatments for age-related diseases, announces its participation in the 17th edition of the SCWD Congress (Society on Sarcopenia, Cachexia & Wasting Disorders), taking place from December 6 to 8, 2024, in Washington, D.C.

As part of the congress, Biophytis will host an Obesity Investor Call on the topic: "GLP-1 RA weight loss therapy-induced muscle loss: A medical need to explore?". The panel of experts will feature key opinion leaders in clinical and medical research:

•       Professor Roger Fielding, Professor of Nutrition and Medicine, Tufts University

•       Professor Marc André Cornier, Endocrinologist, Medical University of South Carolina

•       Professor William Evans, Associate Professor of Human Nutrition, University of California, Berkeley

This session will provide participants with a deeper understanding of the clinical implications and potential therapeutic solutions to counter the side effects of GLP-1 RA obesity treatments. Stanislas Veillet, CEO and Founder of Biophytis, will present the company’s strategic positioning in this field, and the session will be moderated by Rob Van Maanen, Chief Medical Officer of Biophytis.

The event will take place on Friday, December 6, at 12:45 PM ET (6:45 PM CET). Analysts and investors can register and join the event remotely via this link: https://uptownevents-couk.zoom.us/webinar/register/WN_HfHAmCayQ76gcpFw9MGT6Q

*   *   *   *

About BIOPHYTIS

Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for agerelated diseases.  BIO101 (20-hydroxyecdysone), our lead drug candidate,  is  a  small  molecule  in development  for muscular diseases (sarcopenia, Phase 3 ready to start, and Duchenne muscular dystrophy, Phase 1-2 to be started), respiratory diseases (COVID-19, Phase 2-3 completed), and metabolic disorders (obesity, Phase 2 to be started). The company is headquartered in Paris, France, with subsidiaries in

Cambridge, Massachusetts, USA, and Brazil. The Company’s ordinary shares are listed on Euronext Growth Paris (ALBPS - FR001400OLP5) and its ADS (American Depositary Shares) are listed on the OTC market (BPTSY - US 09076G401). For more information, visit www.biophytis.com. 

Page 1 sur 2

Communiqué de presse

Disclaimer

This  press  release  contains  forward-looking  statements.  Forward-looking  statements  include  all statements  that  are  not  historical  facts.  In  some  cases,  you  can  identify  these  forward-looking statements by the use of words such as "outlook,"  "believes,"  "expects,"  "potential," "continues," "may,"    "will,"    "should,"    "could,"      "seeks,"  "predicts,"  "intends,"  "trends,"  "plans,"  "estimates," "anticipates" or the negative version of these words or other comparable words. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable.  However, there can be  no  assurance  that the statements contained in such forward-looking statements  will be  verified, which are subject to various risks and uncertainties. The forward- looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Please also refer to the "Risk and uncertainties the Company is to face» section from the Company’s 2023 Financial Report available on BIOPHYTIS website

(www.biophytis.com) and as exposed in the "Risk Factors" section of form 20-F as well as other forms filed with the SEC (Securities and Exchange Commission, USA). We undertake no obligation  to  publicly  update  or  review  any  forward-looking  statement,  whether  as  a  result  of  new information, future developments or otherwise, except as required by law.

Contact Biophytis 

Investor relations

Investors@biophytis.com

Media contacts

Antoine Denry: antoine.denry@taddeo.fr – +33 6 18 07 83 27

Inès de Mandiargues: ines.demandiargues@taddeo.fr - +33 6 16 16 51 78

Page 2 sur 2